Huge revenue loss Galapagos expected

Huge decrease Galapagos expected

Over the past book year the analyst estimate the revenue to be around 94,47 million euros. This is way more than the 2014's revenue of 90 billion euros. The consensus of the analysts for 2015 is a net loss of 87,87 million euros.

For 2015 the consensus of the earnings per share of Galapagos is at loss of 1,13 euros. Based on this the price/earnings-ratio equals -35,54.

For this year the analysts don't expect Galapagos to pay any dividends. 0On average the stocks in this sector yield a dividend return of around 0,22 percent.

The stock Galapagos is covered by 11 analysts. The average target price for Galapagos is at 61,45 euros. This is 542100 percent more than the current stock price of 40,16 euros.

The stocks MDxHealth, IBA and Ablynx in the sector biotech sector have the most buy recommendations. The 3 most recent recommendations for the biotech sector were provided by Credit Suisse (hold, 50,00 euros), DeGroof Petercam (buy, 60,00 euros) and Goldman Sachs (hold, 56,00 euros).

Galapagos's book value/price equals 0,17. The biotech company now trades at a Shiller PE of 1.36. The stock now trades at 40,16 euros. This equals 32 times the 2014's earnings per share.